Vascular endothelial growth factor (VEGF) induces osteoclast differentiation as well as neovascularization by binding to the fms-like tyrosine kinase (Flt)-1 and fetal liver kinase (Flk)-1 receptors. The Flt-4 receptor also plays an important role in angiogenesis and lymphangiogenesis. The purpose of this study was to investigate the functions of Flt-4 in the signaling pathway of osteoclast differentiation. We examined the expression of Flt-4 on osteoclast precursor cells (OCPs), and the ability of recombinant human (rh) VEGF-D, one of the ligands of Flt-4, to stimulate the phosphorylation of extracellular-regulated kinase1/2 (ERK1/2) and to activate the nuclear factor-kappa B (NF-κB) pathway in OCPs. The number of osteoclasts induced by injection of rhVEGF-D in osteopetrotic (op/op) mice was also evaluated in the absence or presence of neutralizing antibodies to Flt-4. Flt-4 expression was detected on OCPs at both gene and protein levels and stimulation of Flt-4 by rhVEGF-D might induce activation of mitogen-activated protein kinase (MAPK) and NF-κB pathways for induction of osteoclast differentiation. Moreover, the number of osteoclasts in op/op mice increased after injection of rhVEGF-D, but was significantly reduced by the injection of Flt-4 neutralizing antibodies. We have therefore shown that Flt-4 expressed on OCPs, might activate MAPK and NF-κB pathways and played an important role in osteoclast differentiation.
Vascular endothelial growth factor (VEGF) can induce neovascularization (15) . Two specific tyrosine kinase receptors for VEGF have been identified, namely the fms-like tyrosine kinase (Flt)-1 and fetal liver kinase (Flk)-1 which are specifically expressed on vascular endothelial cells and mature osteoclasts (4, 16, 19) . Furthermore, previous studies have demonstrated that recombinant human (rh) VEGF can induce the production of a large number of osteoclasts in osteopetrotic (op/op) mice (17) . These mice are characterized by a deficiency in osteoclasts, monocytes, and macrophages that is caused by the absence of a functional macrophage-colony stimulating factor (M-CSF) (6, 10, 17, 22, 23) . These findings indicate that the VEGF signaling pathway leading to osteoclast differentiation involves signaling through both of these VEGF receptors. Orthodontic tooth movement and related tissue remodeling are achieved by osteoclastic bone resorption followed by osteoblastic new bone formation. Our recent study has demonstrated that VEGF is expressed by osteoblasts located on the tension side of the alveolar bone during experimental tooth movement (12) . Furthermore, the number of osteoclasts and the amount of tooth movement were enhanced Seika, Tokyo, Japan), 250 μg/mL amphotericin B (Nacalai Tesque, Kyoto, Japan), 60 μg/mL kanamycin (Meiji Seika) and 50 ng/mL rhM-CSF (R&D Systems Inc., Minneapolis, USA) at 37°C in a humidified atmosphere of 5% CO 2 .
Total RNA extraction and cDNA synthesis. Total RNA was isolated from cultured cells using a Quickprep Total RNA extraction kit (Amersham Biosciences, Tokyo, Japan). Single stranded cDNA was synthesized from 1 μg total RNA by RT-PCR using an Oligo (dT) primer (Toyobo, Osaka, Japan) and a Rever Tra Ace-α first strand cDNA synthesis kit (Toyobo).
RT-PCR analysis. RT-PCR analysis was performed using 1 μL of cDNA and amplification was carried out for 40 cycles of 45 s at 94°C, 45 s at 53°C, and 45 s at 72°C. The primers for Flt-4 amplification were purchased from R&D Systems Inc. The PCR products were analyzed by 1% agarose gel electrophoresis and visualized by ethidium bromide staining. Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) was also obtained by RT-PCR from the same cells with specific primers and used as a positive control.
Protein extraction and Western blotting analysis.
For Western blotting analysis, mouse OCPs were washed with cold phosphate-buffered saline (PBS), and lysed in a Triton buffer consisting of 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 0.1% Triton X-100, 1 mM ethylenediaminetetraacetic acid (EDTA), and 50 mM NaF with added protease inhibitors. Protein aliquots of 30 μg were separated by electrophoresis on a 7.0% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Whatman, Dassel, Germany). Recombinant mouse Flt-4 chimera (R&D Systems Inc.) was used as positive control. After blocking the membrane with 5% skim milk, the membrane was incubated with rabbit anti-Flt-4 polyclonal antibodies (LAB VISION, Fremont, USA) and peroxidase-conjugated anti-rabbit IgG antibodies. Immunoreactive proteins were visualized with ECL reagents (Amersham Pharmacia Biotech, Buckinghamshire, UK).
Protein extraction and Western blotting procedures for analysis of the phosphorylation of cellular proteins.
To investigate the activation of ERK1/2 and NF-κB pathway, mouse OCPs were cultured in α-modified MEM with 0.1% FBS and without M-CSF for 24 h. Then, the cells were treated with by injection of rhVEGF (11, 12) . Moreover, it has been reported that VEGF, expressed by periodontal ligament fibroblasts, may also induce angiogenesis in a process involving mechanical stimuli (25) . From these results, it is speculated that a chain reaction of angiogenesis and bone remodeling may be promoted by VEGF. VEGF family receptors are widely expressed in embryonic endothelium but postnatally their expression is restricted to lymphatic endothelial cells and some venules (9) . In a recent study it has been demonstrated that the Flt-4 can be up-regulated on the vascular endothelium of tumors (21) and during wound healing (18) . The ligands of Flt-4 are two isoforms of the VEGF family, VEGF-C and VEGF-D, and VEGF-D mRNA is expressed most abundantly in the heart, lung, skeletal muscle, colon, and the small intestine in adult human tissues (1) . Furthermore, a recent study has reported that heterodimerization with Flk-1 is necessary for Flt-4 activity (2). It has therefore been speculated that the signaling pathway activated by VEGF-C and VEGF-D through the Flt-4 receptor plays an important role in lymphangiogenesis and angiogenesis. However, in contrast to the situation with Flt-1 and Flk-1, the interaction of Flt-4 with its ligands and the signaling pathway in osteoclast differentiation remain unclear. The present study was designed to clarify the role and signaling mechanism of Flt-4 in osteoclast induction. For this purpose we investigated the expression of Flt-4 on osteoclast precursor cells (OCPs) and the signaling pathway activated by binding of rhVEGF-D. In previous studies, Flt-4 was shown to induce the phosphorylation and activation of important survival signaling molecules such as the mitogen-activated protein kinases (MAPK) (5) . Therefore, we assayed the activation of extracellular-regulated kinase 1/2 (ERK1/2) and the nuclear factor-kappa B (NF-κB) pathway in particular. Furthermore, we examined the effects of injection of the Flt-4 ligand rhVEGF-D on the induction of osteoclasts in op/op mice and the influence of Flt-4 and Flk-1 neutralizing antibodies on VEGF-D-induced osteoclasts in these mice.
MATERIALS AND METHODS
Cell culture. Mouse OCPs, purchased from Cell Garage (Tokyo, Japan), were cultured in α-modified MEM (Sigma, St. Louis, USA) containing 10% fetal bovine serum (FBS) (Biological Industries, Kibbutz Beit-Haemek, Israel), 32 U/mL penicillin G (Meiji fin. The femurs were cut into longitudinal sections of 7 μm thickness. The longitudinal sections of the median portion of whole femurs were stained with tartrate-resistant acid phosphatase (TRAP), and counterstained with hematoxylin. The number of multi-nucleated, TRAP-positive cells that present in a defined area of 1600 × 7000 μm on the sections of mice femurs were counted on five sections from each of five mice for each group as described previously (10, 17) .
Statistical analyses.
To determine the statistical significance of differences in the number of osteoclasts among the various groups of mice, we performed an analysis of variance (ANOVA) and multiple comparison tests (Fisher) using Statview ® (Abacus Concepts, Inc., Berkeley, USA).
RESULTS

Expression of Flt-4 and stimulation of the ERK1/2 and NF-kB pathways by rhVEGF-D in OCPs
To investigate gene expression of Flt-4 in OCPs RT-PCR analysis was performed on cells cultured in the presence of M-CSF. Flt-4 expression was detected in OCPs and the amplified Flt-4 cDNA migrated with a molecular weight of 260 bp whereas the amplified positive control, G3PDH, migrated with a molecular weight of 450 bp (Fig. 1A) . The cellular protein expression of Flt-4 was analyzed by Western blotting of OCP cell lysates with a specific antiFlt-4 antibody. An immunoreactive protein band of 150 kDa, which co-migrated with a recombinant mouse Flt-4 chimera that was used as a positive control, was observed (Fig. 1B) . Activation of the ERK1/2 and NF-κB pathways by rhVEGF-D was assayed by Western blot of OCP cells that had been cultured in the absence or presence of 100 ng/mL rhVEGF-D for 10 min. Using phospho-specific antibodies immunoreactive protein bands of 42 and 44 kDa, which correspond to phosphorylated and activated ERK 1/2, and of 37 kDa which corresponds to phosphorylated I-κB-α, were clearly detected in the lanes of cells treated with VEGF-D, but not in control lanes (Fig. 1C) .
Effect of rhVEGF-D injection on the induction of osteoclasts in mice
Three days after a single injection of 5 or 10 μg rh-VEGF-D into op/op mice, a large number of osteoclasts appeared in the femurs and osteoclasts could be clearly observed ( Fig. 2A) . In contrast, only a few osteoclasts were detected in the femurs of con-100 ng/mL rhVEGF-D (R&D Systems Inc.) for 10 min. The cells were washed with cold PBS, and lysed in a Triton buffer consisting of 50 mM TrisHCl (pH 7.5), 250 mM NaCl, 0.1% Triton X-100, 1 mM EDTA, and 50 mM NaF with added protease inhibitors. Protein aliquots of 30 μg were separated by electrophoresis in an 8.0% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. After blocking the membrane with 3% bovine serum albumin, the membrane was incubated with a mouse anti-phospho-ERK monoclonal antibody that is specific for the activated form of ERK, or a mouse anti-phospho-I-κB-α monoclonal antibody (SANTA CRUZ BIOTECHNOLOGY, INC, California, USA), and peroxidase-conjugated anti-mouse IgG antibodies. Immunoreactive proteins were visualized with ECL reagents.
Experimental animals.
A breeding pair of B6C3Fe-a/a-op/+ male and female mice were purchased from Jackson Laboratory (Bar Harbor, USA) and mice with op/op genotypes were raised in our laboratory. Mice with the op/op genotype were assessed by a failure of incisor eruption about 10 days after birth. These mice were fed a granulated diet (CA1; Clea Japan, Tokyo, Japan) until the beginning of the experiments at the age of 11-days. The animals were treated in accordance with the ethical regulations of Hiroshima University Faculty of Dentistry.
Growth factor and antibody treatment of mice.
RhVEGF-D (5 μg) was injected peritoneally into 11-day-old op/op mice, immediately followed by injection of 25 μg of anti-Flt-4 (eBioscience, San Diego, USA) and/or anti-Flk-1 (G-T Research Products, Minneapolis, USA) polyclonal antibodies. Five mice were used for each experiment. Antibodies were injected daily for 3 days and then sacrificed. The two antibodies used have been previously shown to be neutralizing antibodies specific for Flt-4 and Flk-1 respectively (3, 14) . For the control group of mice (n = 5), control IgG was injected immediately following rhVEGF-D injection and then injected daily for 3 days until the end of the experiment.
Histological examination. Three days after a single injection of rhVEGF-D, the mice were killed under general anesthesia with sodium pentobarbital (Abbott Laboratories, Illinois, USA), fixed in 4% paraformaldehyde (Sigma) for 24 h, and rinsed in distilled water. Femurs were decalcified in 14% EDTA (pH 7.4) for 14 days and embedded in paraf-rhVEGF-D than in the control group (P < 0.01), whereas no significant differences were found between mice that were injected with 5 or 10 μg rh-VEGF-D (Fig. 3) . trol mice and the bone marrow cavity was filled with excessive bone trabeculae (Fig. 2B) . The number of osteoclasts in a defined area of 1600 × 7000 μm on the sections of mice femurs was significantly larger in the mice injected with 5 or 10 μg 
Effect of Flt-4 and Flk-1 neutralizing antibodies on osteoclast production induced by rhVEGF-D injection
Injection of Flt-4 or Flk-1 neutralizing antibodies significantly decreased the number of osteoclasts induced by rhVEGF-D (Fig. 4) . Furthermore, the effect was more prominent when both Flt-4 and Flk-1 antibodies were injected simultaneously rather than independently. Thus statistical analysis showed that the number of osteoclasts was significantly less when both antibodies were injected simultaneously than when only the Flt-4 antibody was injected (Fig. 4) .
DISCUSSION
In a previous study of op/op mice that were characterized by a deficiency of M-CSF and a resulting deficiency of osteoclasts, VEGF was shown to be capable of induction of osteoclast differentiation (17) . Receptors specific to VEGF (Flt-1 and Flk-1), were identified and detected on mature osteoclasts at both the gene and protein levels (4, 16, 19) . These receptors could support osteoclastic bone resorption and the survival of mature osteoclasts (16) . However, in contrast to Flt-1 and Flk-1, the role of the VEGF receptor Flt-4 and its ligands in osteoclast differentiation and induction have not been elucidated. In this study, Flt-4 was found to be expressed on OCPs at both the gene and protein levels suggesting that Flt-4 may mediate osteoclast differentiation and induction, leading to osteoclastic bone resorption. Our recent study has demonstrated that VEGF is expressed by osteoblasts located on the tension side of the alveolar bone during experimental tooth movement (12) and that the number of osteoclasts and the amount of tooth movement are enhanced by injection of rhVEGF (11, 12) . Furthermore, injection of VEGF neutralizing antibodies reduced the number of osteoclasts significantly and inhibited the rate of tooth movement (13) . In the present study the number of osteoclasts in mice injected with rh-VEGF-D was significantly larger than in the control mice, and osteoclast induction was significantly inhibited following injection of the Flt-4 neutralizing antibody. These data suggest that Flt-4 exerts an important function in the signaling pathway of osteoclast differentiation, as has been shown for Flt-1 and Flk-1. In previous studies, Flt-4 was shown to induce the phosphorylation and activation of important survival signaling molecules such as the mitogen-activated protein kinases (MAPK) (5) . A protein kinase C (PKC) inhibitor substantially reduced Flt-4-medi- Fig. 3 Effect of rhVEGF-D injection on the number of osteoclasts in op/op mice. The number of osteoclasts, determined by counting the number of TRAP-stained cells in a defined area of 1600 × 7000 μm on the sections of mice femurs, was determined following injection of 5 or 10 μg rh-VEGF-D into op/op mice or in control, non-treated mice. Twenty-two osteoclasts at average were induced following injection of 5 μg rhVEGF-D into op/op mice and this number was significantly higher than the number of osteoclasts observed in non-injected control mice (**P < 0.01). A significant difference in the number of osteoclasts was also found in mice injected with 10 μg rhVEGF-D compared to control mice (**P < 0.01). No significant difference was observed between mice injected with 5 or 10 μg rhVEGF-D. ated MAPK phosphorylation, suggesting that this pathway is regulated mainly via PKC and not via Ras (20, 24) . Such a pathway is specific to tyrosine kinase receptors because PKC-dependent MAPK activation is considered to be employed mainly by certain seven-transmembrane and G-protein-coupled receptors. PKC regulates many endothelial cell processes involved in angiogenesis, including endothelial cell proliferation and migration (7, 8) . In this study, stimulation of an activating phosphorylation of ERK1/2 and activation of the NF-κB pathway by rhVEGF-D in OCPs was confirmed by Western blot analysis. These data suggest that stimulation of Flt-4 by VEGF-D may induce a PKC-dependent activation of the MAPK ERK1/2 and of the NF-κB pathway during osteoclast differentiation.
In conclusion, we have shown a function of Flt-4 in osteoclastic bone resorption, that provides a new insight into the mechanism of bone remodeling. This study also suggests that stimulation of Flt-4 by VEGF-D may induce activation of the MAPK ERK 1/2 and of the NF-κB pathway during osteoclast differentiation. In clinical orthodontics, mechanical retention is essential for stabilizing periodontal tissues after orthodontic treatment. A tensed and deformed periodontal tissue is a cause of relapse of aligned teeth. Therefore, further investigation is required to clarify the detailed mechanism of the effect of VEGF family receptors on osteoclast differentiation, and should be conducted to determine whether this pharmacologic adjunctive approach is appropriate and applicable to bone remodeling during orthodontic treatment.
